Evidence map›Paper›PMID 42474883›Full record

ArticleEJNMMI physics2026

Quantification of image quality and partial volume effect along the axial field-of-view of uMI Panorama GS PET/CT system for multiple radionuclides.

Haiqiong Zhang, Guangjie Yang, Linfeng Li, Meixi Liu, Tong Wang, Xueqian Yang, Ziwei Liang, Mengshi Yan, Hongli Jing, Haiqun Xing and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Haiqiong Zhang *State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Guangjie Yang *State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Linfeng LiState Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Meixi LiuState Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Tong WangState Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Xueqian YangState Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Ziwei LiangDepartment of Nuclear Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102200, China.
Mengshi YanBeijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, 100094, China.
Hongli JingState Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. annsmile1976@sina.com.
Haiqun XingState Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. 15801255152@163.com.
Li HuoState Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. huoli@pumch.cn.ORCID http://orcid.org/0000-0003-1216-083X

Funding

the Beijing Natural Science Foundation L242062the China CDC Key Laboratory of Radiological Protection and Nuclear Emergency 2025CDCRN03the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences CIFMS-2021-I2M-1-002the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences CIFMS-2021-I2M-1-003the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences CIFMS-2021-I2M-1-025the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences CIFMS-2023-I2M-2-002the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences CIFMS-2024-I2M-ZD-001the Clinical and Translational Medicine Research Funding of Chinese Academy of Medical Sciences 2025-I2M-C&T-C-005the National High-Level Hospital Clinical Research Funding 2025-PUMCH-D-003the National Key R&D Program of China 2024YFC2419400the National Natural Science Foundation of China U24A20758
6 · The paper itself

Abstract

purposeThe comprehensive knowledge of how the distinct physical decay characteristics of each radionuclide shape their image quality performance is essential for tailoring acquisition protocols and ensuring optimal clinical applications. Understanding the spatial dependence of the contrast recovery coefficient (CRC) is a prerequisite for robust quantitative image analyses and accurate clinical interpretations, since the partial volume effect (PVE) and the count rate vary along the axial field of view (AFOV). Image quality assessments with various radionuclides were performed on the uMI Panorama GS PET/CT system, with the CRC profile across its extended AFOV also evaluated.

methodsFollowing the NEMA NU 2-2018 standard, the image quality was assessed using the NEMA IEC (NEC) Body Phantom with

resultsThe assessment demonstrated comparable image qualities for

conclusionsAll investigated radionuclides were effectively imaged on the uMI Panorama GS PET/CT system. The AFOV uniformity was quantitatively evaluated based on CRC measurements obtained at multiple positions along the AFOV.

Indexed as

Image quantificationLong axial field-of-view PET/CTMultiple radionuclides

Identifiers

PMID42474883
PMCPMC13661889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.